ClinicalTrials.Veeva

Menu
R

Renal Disease Research Institute | Landry

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Bardoxolone Methyl
Venglustat
Atrasentan
ALLN-177
GFB-887
MK-2060
Reloxaliase
Vonafexor
GZ402671
Lucerastat

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 22 total trials

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-a...

Enrolling
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Drug: Avacopan
Drug: Standard of Care

An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe...

Enrolling
Fabry Disease
Drug: migalastat HCl 150 mg

This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat ve...

Enrolling
Fabry Disease
Drug: Venglustat (GZ402671)
Drug: Agalsidase alfa

A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease. This study includes a sub-study e...

Active, not recruiting
Fabry Disease
Drug: Lucerastat

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular d...

Active, not recruiting
Immunoglobulin A Nephropathy
Alport Syndrome
Drug: Atrasentan

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end s...

Active, not recruiting
End-Stage Renal Disease
End-Stage Kidney Disease
Drug: MK-2060
Drug: Placebo

The objective of CLI-06657AA1-03 (formerly PB-102-F51) is to evaluate the long-term safety, tolerability, and efficacy of 2 mg/kg pegunigalsidase alf...

Active, not recruiting
Fabry Disease
Drug: pegunigalsidase alfa

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Overweight and Obesity
Drug: Retatrutide
Drug: Placebo

The purpose of the study is to demonstrate the safety and efficacy of the Merit WRAPSODY Endovascular Stent Graft for treatment of stenosis or occlus...

Active, not recruiting
Venous Occlusion
Venous Stenosis
Device: Merit WRAPSODY Endovascular Stent Graft
Device: PTA

This study is a proof-of-concept trial of vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome.

Enrolling
Alport Syndrome
Drug: Vonafexor

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

Reata Pharmaceuticals logo
A
Amgen logo
Amicus Therapeutics logo
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
CSL Behring logo
Chiesi logo
C
Enyo Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems